HUTCHMED (China) Ltd Group General Counsel Charles George Rupert Nixon reported compensation-related allocations under the company’s Long Term Incentive Plan. On the reported date, 7,445 ordinary shares from awards granted on August 5, 2024 and 7,644 ordinary shares from awards granted on June 9, 2025 were allocated at a purchase price of zero.
The shares are held by the Long Term Incentive Plan trustee on his behalf and are expected to vest and transfer to his personal account in 2027 and 2028, respectively, subject to the award terms. These are indirect holdings and there were no open-market buys or sells.
HUTCHMED (China) Ltd director and CEO/CSO Su Wei-guo reported new allocations under the company’s Long Term Incentive Plan. On May 20, 2026, awards linked to FY2025 performance resulted in 132,864 ordinary shares from an August 5, 2024 grant and 75,140 ordinary shares from a June 9, 2025 grant being allocated at a purchase price of zero.
These shares are held by the Long Term Incentive Plan trustee on his behalf and are expected to vest, and be transferred to his personal account, in 2027 for the 2024 grant and 2028 for the 2025 grant, subject to the awards’ terms and conditions.
HUTCHMED (China) Ltd reported a Form 4 for Deputy Chief Financial Officer Lorenso Chiu showing allocations under its Long Term Incentive Plan. On May 20, 2026, a plan trustee allocated 8,863 ordinary shares from awards granted on June 9, 2025 and 5,176 ordinary shares from awards granted on August 5, 2024, both at a purchase price of zero. These shares are held indirectly by the Long Term Incentive Plan trustee on his behalf and are expected to vest and transfer to his personal account in 2028 and 2027, respectively, subject to award terms. No open-market buys or sells were reported.
HUTCHMED (China) Ltd filed a Form 4 for former director Tony Shu Kam Mok showing no reportable insider transactions. The filing data list zero purchases, sales, exercises, gifts, or other equity movements, indicating no change in his reportable ownership position during the covered period.
HUTCHMED (China) Limited reports that all resolutions at its May 12, 2026 Annual General Meeting were approved by shareholders on a poll.
Shareholders adopted the audited financial statements for the year ended December 31, 2025, with 440,149,560 votes in favor and only 1,020 against. All nominated directors, including Dr Dan Eldar, Dr Weiguo Su and Chief Financial Officer Johnny Cheng, were re-elected with approval levels generally above 93% of votes cast.
PricewaterhouseCoopers and PricewaterhouseCoopers Zhong Tian LLP were re-appointed as independent auditors. Shareholders also granted directors a general mandate to issue additional shares and a separate mandate to repurchase shares, and approved the adoption of the 2026 Share Option Scheme, which received approximately 90.2% of votes cast in favor.
HUTCHMED (China) Limited has updated the market on its total voting rights. As at April 30, 2026, the company’s issued share capital consisted of 872,335,120 ordinary shares of US$0.10 each, with each share carrying one vote and no shares held in treasury.
The figure of 872,335,120 is the denominator shareholders can use to assess whether they must notify interests or changes in interests under the UK Financial Conduct Authority’s Disclosure Guidance and Transparency Rules. This share capital is equivalent to 872,335,120 depositary interests traded on AIM or 174,467,024 American depositary shares traded on Nasdaq.
HUTCHMED (China) Limited reports that China’s National Medical Products Administration has accepted the New Drug Application for sovleplenib to treat adults with warm antibody autoimmune hemolytic anemia (wAIHA) who responded poorly to prior glucocorticoid therapy. The NDA has priority review status and Breakthrough Therapy Designation, reflecting its potential in a serious disease with limited options.
The filing is backed by the ESLIM-02 Phase II/III trial, where the Phase III segment met its primary endpoint of durable hemoglobin response. Earlier Phase II data in The Lancet Haematology showed hemoglobin benefits versus placebo and response rates up to 66.7% over 24 weeks, with a favorable safety profile. Sovleplenib is also in late-stage development for immune thrombocytopenia, where a separate NDA in China has been accepted with priority review.
HUTCHMED (China) Limited is highlighting new oncology research that will be presented at the AACR Annual Meeting 2026 in San Diego from April 17-22, 2026. The presentations focus on its antibody-targeted therapy conjugate (ATTC) platform and combination regimens for difficult gastrointestinal cancers.
Preclinical data for HMPL-A580, a first-in-class PI3K/PIKK-EGFR ATTC, show potent and selective kinase inhibition with IC50 values around 1–10 nM and strong anti-tumor effects in EGFR-expressing models. In mouse xenograft models, weekly intravenous dosing at 1–10 mg/kg produced dose-dependent tumor growth inhibition and favorable pharmacokinetics in non-human primates.
Updated clinical data will also be presented from a multicenter Phase Ib/II trial of surufatinib plus sintilimab and capecitabine in metastatic small bowel and appendiceal cancers, and from an exploratory Phase II study combining surufatinib with gemcitabine and nab-paclitaxel in locally advanced or metastatic pancreatic ductal adenocarcinoma following induction therapy.
HUTCHMED (China) Limited has furnished its 2025 Annual Report and convened a 2026 hybrid Annual General Meeting, to be held on May 12, 2026 in Hong Kong with online access. Shareholders are asked to re-elect the full board (other than one retiring independent director) and renew general mandates authorizing directors to issue new shares and to repurchase up to 10% of issued shares.
The circular proposes adoption of a 2026 Share Option Scheme, allowing options over up to 5% of the Company’s issued share capital as at adoption, which equals 43,616,381 shares based on 872,327,620 shares outstanding at the latest practicable date. A separate Repurchase Mandate would permit buybacks of up to 87,232,762 shares. The board notes CK Hutchison group holds 332,632,780 shares, or 38.13%, and that full use of the Repurchase Mandate could raise this to 42.37% and potentially trigger a mandatory offer under Hong Kong takeover rules, which the directors state they do not intend.
The scheme includes a minimum 12‑month vesting period (with limited exceptions), performance conditions, a 10‑year option life and a clawback policy linked to any future financial restatements. Detailed AGM logistics cover hybrid attendance, proxy voting deadlines and bad‑weather contingency arrangements.
HUTCHMED (China) Ltd Group General Counsel Charles George Rupert Nixon filed an initial ownership report showing his existing equity interests in the company. He holds share options over 400,000 ordinary shares with a 0.0000 exercise price expiring on December 10, 2029, plus several option grants over American depositary shares with exercise prices between 10.7500 and 35.2100 per ADS and expirations from 2030 to 2033. He also directly owns 143,190 ordinary shares and 41,763 American depositary shares, and has 11,663 ordinary shares held indirectly through a Long Term Incentive Plan trustee, with those awards scheduled to vest in 2027.